Abstract
The development of gene-inactivation systems is an active and important field for both functional genomics and gene therapy. Towards this end, ribozymes (i.e. RNA enzymes), that specifically recognize and subsequently catalyze the cleavage of other target RNA molecules, are attractive molecular tools. Ribozymes represent an interesting alternative to the RNA interference (RNAi) approach for gene inactivation, especially given the fact that RNAi seems to trigger an immunological response and has demonstrated off-target effects. However, the design and optimization of a ribozymebased gene-inactivation system is not a straightforward procedure. Several aspects need to be considered in the experimental design in order to provide a suitable suppression system. In this review we present the advances in this domain made available from work using the hepatitis delta virus (HDV) ribozyme as a cis-acting RNA motif in molecular biology, as well as a trans-acting molecular scissor for the development of a gene-inactivation system. This HDV ribozyme technology possesses several unique features that are all related to the fact that it is the only catalytic cleaving RNA motif that has been discovered in humans.
Keywords: HDV ribozyme, RNA interference, antisense, ribozyme, deoxyribozyme, RNase P, functional genomic, gene therapy
Current Gene Therapy
Title: Development of Ribozyme-Based Gene-Inactivations; The Example of the Hepatitis Delta Virus Ribozyme
Volume: 7 Issue: 3
Author(s): M. Asif-Ullah, Michel Levesque, Gilles Robichaud and Jean-Pierre Perreault
Affiliation:
Keywords: HDV ribozyme, RNA interference, antisense, ribozyme, deoxyribozyme, RNase P, functional genomic, gene therapy
Abstract: The development of gene-inactivation systems is an active and important field for both functional genomics and gene therapy. Towards this end, ribozymes (i.e. RNA enzymes), that specifically recognize and subsequently catalyze the cleavage of other target RNA molecules, are attractive molecular tools. Ribozymes represent an interesting alternative to the RNA interference (RNAi) approach for gene inactivation, especially given the fact that RNAi seems to trigger an immunological response and has demonstrated off-target effects. However, the design and optimization of a ribozymebased gene-inactivation system is not a straightforward procedure. Several aspects need to be considered in the experimental design in order to provide a suitable suppression system. In this review we present the advances in this domain made available from work using the hepatitis delta virus (HDV) ribozyme as a cis-acting RNA motif in molecular biology, as well as a trans-acting molecular scissor for the development of a gene-inactivation system. This HDV ribozyme technology possesses several unique features that are all related to the fact that it is the only catalytic cleaving RNA motif that has been discovered in humans.
Export Options
About this article
Cite this article as:
Asif-Ullah M., Levesque Michel, Robichaud Gilles and Perreault Jean-Pierre, Development of Ribozyme-Based Gene-Inactivations; The Example of the Hepatitis Delta Virus Ribozyme, Current Gene Therapy 2007; 7 (3) . https://dx.doi.org/10.2174/156652307780859008
DOI https://dx.doi.org/10.2174/156652307780859008 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nutraceuticals for Metabolic Syndrome Management: From Laboratory to Benchside
Current Vascular Pharmacology Active-Targeted Nanotherapy Strategies for Prostate Cancer
Current Cancer Drug Targets Rac-1 as a New Therapeutic Target in Cerebro- and Cardio-Vascular Diseases
Current Drug Targets Longevity Pathways: HSF1 and FoxO Pathways, a New Therapeutic Target to Prevent Age-Related Diseases
Current Aging Science Imaging Cellular Receptors in Breast Cancers: An Overview
Current Pharmaceutical Biotechnology Activating Mutations of ESR1, BRCA1 and CYP19 Aromatase Genes Confer Tumor Response in Breast Cancers Treated with Antiestrogens
Recent Patents on Anti-Cancer Drug Discovery The GLUTs Family - Lessons from Transgenic Mice
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Relationship Between Inflammation, Dyslipidemia and Physical Exercise: From the Epidemiological to Molecular Approach
Current Diabetes Reviews Hypocalcemia Induced by Raloxifene
Current Drug Safety Neuropsychiatric and General Interactions of Natural and Synthetic Cannabinoids with Drugs of Abuse and Medicines
CNS & Neurological Disorders - Drug Targets Targeting CCK Receptors in Human Cancers
Current Topics in Medicinal Chemistry Neurological Disorders in Medical Use of <i>Cannabis</i>: An Update
CNS & Neurological Disorders - Drug Targets Neuronal and Glial Cell Abnormality as Predictors of Progression of Diabetic Retinopathy
Current Pharmaceutical Design Adiponectin: A Key Player in Obesity Related Disorders
Current Pharmaceutical Design Synthetic Peptide Drugs for Targeting Skin Cancer: Malignant Melanoma and Melanotic Lesions
Current Medicinal Chemistry Molecular Mechanisms Underlying the Dedifferentiation Process of Isolated Hepatocytes and Their Cultures
Current Drug Metabolism Single-Photon Emission Computed Tomography Tracers for Predicting and Monitoring Cancer Therapy
Current Pharmaceutical Biotechnology Long-Term Survivors of Cancer in Childhood and Adolescence
Current Pediatric Reviews The “Big Five” Phytochemicals Targeting Cancer Stem Cells: Curcumin, EGCG, Sulforaphane, Resveratrol and Genistein
Current Medicinal Chemistry Combating Diseases with Computational Strategies Used for Drug Design and Discovery
Current Topics in Medicinal Chemistry